Bernstein analyst Lee Hambright lowered the firm’s price target on Insulet (PODD) to $380 from $410 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target lowered to $365 from $388 at Goldman Sachs
- Insulet’s New Omnipod M Study Targets the Untapped Type 2 Diabetes Pump Market
- Insulet’s Omnipod SmartAdjust 2.0 Trial Wraps Up: What Investors Should Watch Next
- Insulet price target lowered to $390 from $412 at Truist
- Insulet Revises Annual Incentive Plan for 2026